First Patient Included Marks Major Milestone in EU-Funded Clinical Trial

Fantastic news!

PsyPal has reached a major milestone with the inclusion of its first patient in the multi-site clinical trial investigating psilocybin therapy for psychological and existential distress in people with progressive, life-limiting illnesses.

The EPA is proud to be a part of this project, as it is an essential study that aims to offer support to people in need of palliative care, who can endure overwhelming existential distress. Our goal is to continuously provide for patients in needs, and this step is bringing us closer to this objective.

Discover the full press release here.